Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RO5508887
- Development stage
- Phase 1
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral (based On Typical Administration For Similar Small Molecules; Specific Route Not Explicitly Stated But Inferred From Clinical Trial Design)
01
Overview
RO5508887 is a potent small molecule inhibitor of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), also known as beta-secretase. It is an aminooxazoline derivative that inhibits BACE1 with an IC50 of approximately 30 nM and is similarly potent against BACE2. The compound was developed by Roche for the treatment of Alzheimer's disease and entered clinical trials in 2011. However, development was discontinued in October 2013 without public explanation. Preclinical studies demonstrated its efficacy in reducing amyloid-beta production, and it was also studied in combination with anti-Aβ antibody gantenerumab[1][2][3][4][5][7].
- Other names
- 1310347-50-2
02
Targets
BACE1 (Beta-site APP-cleaving enzyme 1)BACE2 (Beta-site amyloid precursor protein cleaving enzyme 2)
Beyond the preview
Go deeper on RO5508887.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RO5508887.